(NewsDirect)
Race Oncology Ltd (ASX:RAC) CEO Damian Clarke-Bruce tells Proactivethat they will shortly start assessing the cardiovascular-protectiveproperties of Zantrene® (bisantrene) treatment in the observationalstage of a Phase 1/2b clinical trial in breast cancer patients treatedwith doxorubicin and cyclophosphamide with at least two cardiovascularrisk factors. Resolutum Global, Beyond Drug Development and NSWRegional Biospecimen & Research Services have been appointed tosupport the clinical program.
ContactDetails
Gregg Castano
+1 203-762-5649
Copyright (c) 2023 TheNewswire - All rights reserved.